Facebook Twitter LinkedIn
CIS

CIS

The science and practice of human immunology

The science and practice of human immunology

Table of Compounds

Nomenclature »

 

 

 

Non-proprietary Name Brand Name Molecular Target Molecular Structure Licensed Indication Manufacturer and/or Distributor Initial FDA Approval
Abatacept Orencia B7-1 (CD80),
B7-2 (CD86)
CTLA4-Human IgG1 Fusion protein Rheumatoid Arthritis,
Juvenile Rheumatoid Arthritis
Bristol Myers Squibb 2005
Abciximab ReoPro Glycoprotein (GP) IIb/IIIa receptor of human platelets chimeric/human monoclonal antibody; Fab portion cardiac ischemia Centocor
Eli Lilly
1994
Adalimumab Humira TNFα (Tumor Necrosis Factor-alpha) human IgG1κ, recombinant rheumatoid arthritis;
juvenile idiopathic arthritis;
psoriatic arthritis;
ankylosing spondylitis;
Crohn's disease;
plaque psoriasis
Abbott 2002
Ado-trastuzumab Kadcyla HER-2 humanized IgG1κ mAb HER-2 positive metastatic breast cancer Genentech/
Immunogen
2013
Aflibercept Eylea VEGF, PIGF Fusion protein:  IgG Fc, and ligand binding domains of VEGFR-1, VEGFR-2 Wet age-related macular edema;
Macular edema following central retinal vein occlusion
Regeneron/Sanofi-Aventis 2011
Aldesleukin Proleukin IL-2R Modified recombinant human IL-2 Metastatic renal cell carcinoma, metastatic melanoma Prometheus Laboratories 1992
Alemtuzumab Campath CD52 (cell surface glycoprotein) humanized IgG1κ, recombinant Chronic B-lymphocyte Leukemia (B-CLL) Genzyme
Bayer Healthcare Pharmaceuticals
2001
Anakinra Kineret Interleukin-1 type I receptor (IL-1RI) recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs Amgen 2001
Basiliximab Simulect CD25 (IL-2Rα) chimeric IgG1κ, recombinant prophylaxis of acute organ rejection in adults following cadaveric- or living-donor renal transplantation Novartis 1998
Non-proprietary Name Brand Name Molecular Target Molecular Structure Licensed Indication Manufacturer and/or Distributor Initial FDA Approval
Belatacept Nolojix CD80, CD86 CTLA fused to the Fc portion of human IgG1 Prophylaxis of organ rejection after kidney transplant Bristol-Meyers-Squibb 2011
Belimumab Benlysta BLyS (B-lymphocyte stimulator) Human monocolonal antibody IgG1-lambda Systematic lupus erythematosus Human Genome Sciences/ GlaxoSmithKline 2011
Bevacizumab Avastin VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-small cell lung cancer Genentech 2004
Brentuximab vedotin Adcetris CD30 Chimeric IgG1k monoclonal antibody conjugated to a microtubule disrupting agent MMAE by a protease-cleavable linker Hodgkin’s lymphoma, Systemic anaplastic large cell lymphoma SeattleGenetics 2011
C1 esterase inhibitor Cynrize C1r and C1s of the classical complement pathways, MASP-1 and MASP-2 of the MBL complement pathway, kallikrein, factors Xia and XIIa Purified physiological protein Hereditary angioneurotic edema Sanquin/ViroPharma 2008
Canakinumab Ilaris Interleukin-1 beta (IL-1β) Human anti-human-IL-1β IgG1 monoclonal antibody Treatment of CAPS, including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS), in adults and children 4 years of age and older Novartis 2009
Capromab pendetide Protascint Prostate Specific Membrane Antigen (PSMA) murine monoclonal IgG1κ, indium-111 labeled Diagnostic imaging of metastatic prostate cancer in newly diagnosed, high risk patients Cytogen 1996
Non-proprietary Name Brand Name Molecular Target Molecular Structure Licensed Indication Manufacturer and/or Distributor Initial FDA Approval
Certolizumab pegol Cimzia TNFα humanized, recombinant Fab' fragment conjugated to polyethylene glycol Crohn's disease UCB Pharma
Nektar
(XOMA)
2008
Cetuximab Erbitux EGF (Epidermal Growth Factor) receptor chimeric monoclonal antibody metastatic colorectal cancer, head and neck cancer Imclone & Bristol-Meyers Squibb (North America);
Merck KGaA (other areas)
2004
Denileukin diftitox ONTAK IL-2 Receptor recombinant fusion protein expressing amino acid residues of diphtheria toxin fragment A & B, followed by the sequence for IL-2 recurrent CD25 positive, cutaneous T-cell lymphoma Eisai 1999
Denosumab Xgeva

Prolia
RANKL (receptor activator of nuclear factor kappa-B ligand) Human IgG2 monoclonal antibody
Xgeva:  Prevention of skeletal-related events in patients with bone metastases from solid tumors
Prolia:  treatment of postmenopausal osteoporosis; treatment of men receiving androgen deprivation therapy for non-metastatic prostate cancer; treatment of woman receiving adjuvant aromatase inhibitor therapy for breast cancer
Amgen 2010
Ecallantide Kalbitor Plasma kallikrein Recombinant (60 amino acid) variant of human aprotinin, selected from a phage display library Acute attacks of hereditary angioedema affecting any body part in patients 16 years of age and older Dyax Corporation 2009
Eculizumab Soliris complement protein C5 humanized Paroxysmal nocturnal hemoglobinuria Alexion Pharmaceuticals 2011
Non-proprietary Name Brand Name Molecular Target Molecular Structure Licensed Indication Manufacturer and/or Distributor Initial FDA Approval
Etanercept Enbrel TNFα and TNFβ TNFR-IgG1 Fc fusion protein Rheumatoid Arthritis;
Juvenile Idiopathic Arthritis;
psoriatic arthritis;
ankylosing spondylitis;
plaque psoriasis
Amgen
Wyeth
1998
Golimumab Simponi TNFα (Tumor Necrosis Factor-alpha) human IgG1κ, recombinant Rheumatoid arthritis
Psoriatic arthritis
Ankylosing Spondylitis
Janssen Biotech 2009
Ibritumomab tiuxetan Zevalin CD20 murine IgG1κ monoclonal antibody, conjugated to a chelator (tiuxetan) for labeling with Indium-111 or Yttrium-90 non-Hodgkins Lymphoma (CD20 positive, low-grade or follicular) which is relapsed or refractory to rituximab, in combination with rituximab Cell Therapeutics
Biogen Idec
2002
Icatibant Firazyr Bradykinin B2 receptor Synthetic decapeptide with five non-proteinogenic amino acids Acute attacks of hereditary angioedema affecting any body part in patients 18 years of age and older Shire Human Genetic Therapies, Inc 2011
Infliximab Remicade TNFα (Tumor Necrosis Factor-alpha) chimeric IgG1k, recombinant monoclonal antibody Rheumatoid arthritis (in combination with methotrexate)
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Crohn's disease
Pediatric Crohn’s disease
Ulcerative colitis
Pediatric ulcerative colitis
Janssen Biotech 1998
Non-proprietary Name Brand name Molecular Target Molecular Structure Licensed indication Manufacturer and/or Distributor Initial FDA Approval
Interferon alpha-2b Intron A Type I interferon receptors recombinant, human hairy cell leukemia;
malignant melanoma;
follicular lymphoma;
condylomata acuminata;
AIDS-related Kaposi's sarcoma;
chronic hepatitis B;
chronic hepatitis C
Schering 1986
Interferon beta-1a Rebif Type I interferon receptors recombinant, human, glycosylated relapsing forms of multiple sclerosis
EMD Serono
Pfizer
2002
Interferon beta-1a Avonex Type I interferon receptors recombinant human physiologic protien, glycosylated relapsing forms of multiple sclerosis Biogen Idec 1996
Interferon beta-1b Extavia

Betaseron
Type I interferon receptors recombinant, human relapsing forms of multiple sclerosis Novartis

Bayer
1993
Interferon gamma Actimmune Type II interferon receptors recombinant, human chronic granulomatous disease;
severe, malignant osteopetrosis
InterMune 1999
Ipilimumab Yervoy CTLA-4 (cytotoxic T-lymphocyte-associated antigen) Chimeric IgG1κ, recombinant monoclonal antibody Melanoma that is metastatic or unresectable Bristol-Myers Squibb 2011
Mepolizumab Nucala IL-5 Humanized IgG1κ monoclonal antibody severe eosinophilic asthma in patients aged 12 years or older GlaxoSmithKline 2015
Non-proprietary Name Brand name Molecular Target Molecular Structure Licensed indication Manufacturer and/or Distributor Initial FDA Approval
Natalizumab Tysabri α4-subunit of α4-β1 and α4-β7 integrins; blocks binding of VLA4 to VCAM-1 and binding of α4-β7 to MADCAM-1 humanized IgG4κ Relapsing forms of MS, Crohn's Disease Elan Pharmaceuticals & Biogen Idec 2004
Obinutuzumab Gazyva CD20.14 humanized IgG1 monoclonal antibody Chronic Lymphocytic Leukemia in combination with chemotherapy in treatment-naïve patients Hoffmann-La Roche, Genentech Inc, Biogen Idec 2013
Ofatumumab Arzerra CD20 Human IgG1κ monoclonal antibody, recombinant Chronic lymphocytic leukemia resistant to fludarabine and alemtuzumab Glaxo Smith Kline 2009
Omalizumab Xolair IgE humanized IgG1κ, recombinant moderate to severe IgE-mediated, persistent asthma (US) or severe asthma (EU), in adults and children over 12 years old, inadequately controlled by inhaled corticosteroid treatment Genentech &
Novartis
2003
Oprelvekin Neumega Interleukin-11 receptor recombinant, human IL-11 risk of, or pre-existing, severe thrombocytopenia and/or need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies Wyeth 1997
Palivizumab Synagis RSV F (fusion) protein humanized IgG1κ prevention of serious lower respiratory
tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease
Medimmune 1998
Panitumumab   Vectibex human EGFR (Epidermal Growth Factor Receptor) recombinant human IgG2κ monoclonal antibody treatment of  EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens Amgen 2006
Peginterferon alpha-2a Pegasys Type I interferon receptors Recombinant human physiological protein, Type I interferon, conjugated to polyethylene glycol Chronic hepatitis C
Chronic hepatitis B
Hoffmann-La Roche/Genentech 2002
Non-proprietary Name Brand name Molecular Target Molecular Structure Licensed indication Manufacturer and/or Distributor Initial FDA Approval
Peginterferon alpha-2b Pegintron Type I interferon receptors Recombinant human physiologic protein covalently conjugated to polyethylene glycol Chronic hepatitis C Schering (Merck) 2001
Pertuzumab Perjeta HER2 Humanized IgG1κ monoclonal antibody, glycosylated HER2 overexpressing breast cancer, in combination with trastuzumab and docetaxel Genentech 2012
Ranibizumab Lucentis VEGF-A humanized IgG1κ Fab fragment neovascular (wet) age-related macular degeneration Genentech
(XOMA)
2006
Raxibacumab Raxibacumab Anthrax toxin Human IgG1-lambda mAB inhalation anthrax Human Genome Sciences/ GlaxoSmithKline 2012
Rilonacept Arcalyst IL-1 beta (IL-1β) Dimeric fusion protein; ligand-binding domains of IL-1 receptor (IL-1R) & IL-1 receptor accessory protein (IL-1RAcP) linked to human IgG1 cryopyrin-associated periodic fever syndromes (CAPS), including Muckle-Wells syndrome (MWS) and familial cold autinflammatory syndrome (FCAS) in children 12 years and older Regeneron 2008
Rituximab Rituxan CD20 chimeric IgG1κ, recombinant rheumatoid arthritis; B-cell non-Hodgkin's lymphoma Genentech
Biogen Idec
2011
Secukinumab Cosentyx IL17A human immunoglobulin G1k (IgG1k) subclass monoclonal antibody moderate to severe plaque psoriasis; ankylosing spondylitis; psoriatic arthritis Novartis 2015
Sipuleucel-T Provenge Prostate acid phosphatase expressing cells Prostate acid phosphatase stimulated autologous peripheral blood mononuclear cells Metastatic prostate cancer that is minimally symptomatic and hormone refractory Dendreon 2010
Tocilizumab Actemra IL-6 receptor (IL-6R) humanized, recombinant Rheumatoid Arthritis (Japan), systemic-onset Juvenile Idiopathic Arthritis (Japan) F.Hoffman-La Roche and Chugai Pharmaceuticals 2010
Tositumomab Bexxar CD20 murine, monoclonal; covalently bound to Iodine-131 non-Hodgkins Lymphoma (CD20 positive, follicular) which is refractory to rituximab and relapsed following chemotherapy GlaxoSmithKline 1993
Trastuzumab Herceptin c-erbB2/HER2 humanized receptor antagonist HER2 overexpressing breast cancer Genentech 1998
Ustekinumab Stelara p40 subunit of the cyokines IL-12 and IL-23 human IgG1k monoclonal antibody adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy Centocor Ortho Biotech Inc. 2009
Ziv-aflibercept Zaltrap VEGF, PIGR Fusion protein: IgG Fc, and ligand binding domains of VEGFR-1 and VEGFR-2 Metastatic colorectal cancer Regeneron/ Sanofi-Aventis 2012
Non-proprietary Name Brand Name Molecular Target Molecular Structure Licensed Indication Manufacturer and/or Distributor Initial FDA Approval

 

 

Last updated: December 9, 2016